Responder rates with eptinezumab over 24 weeks in patients with prior preventive migraine treatment failures: post hoc analysis of the DELIVER randomized clinical trial.

Messoud Ashina,Richard B Lipton,Jessica Ailani,Jan Versijpt,Simona Sacco,Dimos D Mitsikostas,Cecilie Laurberg Christoffersen,Bjørn Sperling,Anders Ettrup

European journal of neurology（2023）

引用 0|浏览1

暂无评分

摘要

Across MRR thresholds, most patients who responded to eptinezumab during weeks 1-12 maintained or improved response during weeks 13-24. More than one-third of initial non-responders became responders after their second infusion.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要